STK11 and non-small cell lung carcinoma: All three patients with SD had NSCLC, two of whom had low PD-L1 expression (1-49%), STK11 wildtype but KRAS-mutated adenocarcinoma, and were previously treated with an immune checkpoint inhibitor.